Peripheral arterial disease can involve tissue loss in up to 50% of patients with diabetic foot syndrome (DFS). Consequently, revascularization of narrowed or occluded arteries is one of the most common forms of comprehensive treatment. However, technically successful angioplasty does not always result in the healing of ulcers. The pathomechanism of this phenomenon is still not fully understood, but inadequate angiogenesis in tissue repair may play an essential role. Changes in pro- and anti-angiogenic factors among patients with DFS are not always clear and conclusive. In particular, some studies underline the role of decreased concentration of pro-angiogenic factors and higher levels of anti-angiogenic mediators. Nevertheless, there are still controversial issues, including the paradox of impaired wound healing despite high concentrations of some pro-angiogenic factors, dynamics of their expression during the healing process, and their mutual relationships. Exploring this process among diabetic patients may provide new insight into well-known methods of treatment and show their real benefits and chances for improving outcomes.
SaeediPPetersohnISalpeaP, et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract2019;157:107843.
2.
ReardonRSimringDKimB, et al.The diabetic foot ulcer. Australian Journal of General Practice2020;49:250–255.
3.
van NettenJJBusSAApelqvistJ, et al.Definitions and criteria for diabetic foot disease. Diabetes/Metabolism Research and Reviews2020;36 (Suppl 1):e3268–e3276.
4.
ArmstrongDGBoultonAJMBusSA. Diabetic foot ulcers and their recurrence. N Engl J Med2017;376:2367–2375.
5.
JhambSVangavetiVNMalabuUH. Genetic and molecular basis of diabetic foot ulcers: clinical review. J Tissue Viability2016;25:229–236.
6.
ArmstrongDGCohenKCourricS, et al.Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol2011;5:1591–1595.
7.
PatelSSrivastavaSSinghMR, et al.Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother2019;112:108615.
8.
PrompersLSchaperNApelqvistJ, et al.Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia2008;51:747–755.
9.
BrownriggJRWDaveyJHoltPJ, et al.The association of ulceration of the foot with cardiovascular and all-Cause mortality in patients with diabetes: a meta-analysis. Diabetologia2012;55:2906–2912.
10.
ArmstrongDGSwerdlowMAArmstrongAA, et al.Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res2020;13:16–25.
11.
SchaperNCvan NettenJJApelqvistJ, et al.Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes/Metab Res Rev2020;36(Suppl 1):e3266–10.
12.
PrompersLHuijbertsMApelqvistJ, et al.High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the eurodiale study. Diabetologia2007;50:18–25.
13.
CriquiMHAboyansV. Epidemiology of peripheral artery disease. Circ Res2015;116:1509–1526.
14.
YangS-lZhuL-yHanR, et al.Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes2017;9:133–140.
15.
ForsytheROBrownriggJHinchliffeRJ. Peripheral arterial disease and revascularization of the diabeticfoot. Diabetes Obes Metab2014;17(5):435−444.
16.
ForsytheROApelqvistJBoykoEJ, et al.Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes/Metab Res Rev2020;36(Suppl 1):e3279.
17.
FalangaV. Wound healing and its impairment in the diabetic foot. Lancet2005;366:1736–1743.
18.
ShawTJMartinP. Wound repair at a glance. J Cell Sci2009;122:3209–3213.
FalangaV. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cell Mol Dis2004;32:88–94.
21.
OkonkwoUADipietroLA. Diabetes and wound angiogenesis. Int J Mol Sci2017;18:1–15.
22.
ZhouKMaYBroganMS. Chronic and non-healing wounds: the story of vascular endothelial growth factor. Med Hypotheses2015;85:399–404.
23.
NagyJADvorakAMDvorakHF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol2007;2:251–275.
24.
FongG-HRossantJGertsensteinM, et al.Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature1995;376:66–70.
25.
HiratsukaSMinowaOKunoJ, et al.Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci Unit States Am1998;95:9349–9354.
26.
HoTKShiwenXAbrahamD, et al.Stromal-cell-derived factor-1 (SDF-1)/CXCL12 as potential target of therapeutic angiogenesis in critical leg ischaemia. Cardiol Res Pract2012;2012:143209.
27.
CeradiniDJKulkarniARCallaghanMJ, et al.Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med2004;10:858–864.
28.
CatrinaS-BZhengX. Disturbed hypoxic responses as a pathogenic mechanism of diabetic foot ulcers. Diabetes Metabol Res Rev2016;32:179–185.
29.
Abd El-KhalikSRHafezYMElkholyRA. The role of circulating soluble fms-like tyrosine kinase-1 in patients with diabetic foot ulcer: a possible mechanism of pathogenesis via a novel link between oxidative stress, inflammation and angiogenesis. Microvasc Res2020;130:103987.
30.
LinC-JLanY-MOuM-Q, et al.Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats. J Endocrinol Invest2019;42:1307–1317.
31.
ThangarajahHYaoDChangEI, et al.The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci Unit States Am2009;106:13505–13510.
32.
Mohajeri-TehraniMRNasiripoorFTorkamanG, et al.Effect of low-intensity direct current on expression of vascular endothelial growth factor and nitric oxide in diabetic foot ulcers. J Rehabil Res Dev2014;51:815–824.
33.
GałkowskaHOlszewskiW. Cellular and molecular basis of impaired healing of diabetic foot ulcers. Pol J Surg2008;79:720–727.
34.
ChenZFuSWuZ, et al.Relationship between plasma angiogenic growth factors and diabetic foot ulcers. Clin Chim Acta2018;482:95–100.
35.
KulwasADrelaEJundziłłW, et al.Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications. J Diabetes Complicat2015;29:686–690.
36.
DrelaEKulwasAJundziłłW, et al.VEGF-A i PDGF-BB - czynniki angiogenne a stopień zaawansowania zespołu stopy cukrzycowej. Endokrynol Pol2014;65:306–312.
37.
GunesAEErenMAKoyuncuI, et al.Investigation of galectin-3 levels in diabetic foot ulcers. J Wound Care2018;27:843–848.
38.
ObaKHosonoKAmanoH, et al.Downregulation of the proangiogenic prostaglandin E receptor EP3 and reduced angiogenesis in a mouse model of diabetes mellitus. Biomed Pharmacother2014;68:1125–1133.
39.
BotusanIRSunkariVGSavuO, et al.Stabilization of HIF-1 is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci Unit States Am2008;105:19426–19431.
40.
XingYLaiJLiuX, et al.Netrin-1 restores cell injury and impaired angiogenesis in vascular endothelial cells upon high glucose by PI3K/AKT-eNOS. J Mol Endocrinol2017;58:167–177.
41.
GalkowskaHWojewodzkaUOlszewskiWL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen2006;14:558–565.
42.
CatrinaS-BOkamotoKPereiraT, et al.Hyperglycemia regulates Hypoxia-Inducible factor-1 protein stability and function. Diabetes2004;53:3226–3232.
43.
AminKNUmapathyDAnandharajA, et al.miR-23c regulates wound healing by targeting stromal cell-derived factor-1α (SDF-1α/CXCL12) among patients with diabetic foot ulcer. Microvasc Res2020;127:103924.
44.
MaceKAYuDHPaydarKZ, et al.Sustained expression ofHif-1αin the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen2007;15:636–645.
45.
GallagherKALiuZ-JXiaoM, et al.Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α. J Clin Invest2007;117:1249–1259.
46.
OdorisioTCianfaraniFFaillaCM, et al.The placenta growth factor in skin angiogenesis. J Dermatol Sci2006;41:11–19.
47.
BarrientosSStojadinovicOGolinkoMS, et al.Perspective article: growth factors and cytokines in wound healing. Wound Repair Regen2008;16:585–601.
48.
PippFHeilMIssbruckerK, et al.VEGFR-1-Selective VEGF homologue PlGF is arteriogenic. Circ Res2003;92:378–385.
49.
CianfaraniFZambrunoGBrogelliL, et al.Placenta growth factor in diabetic wound healing. Am J Pathol2006;169:1167–1182.
50.
GreenPJWalshFSDohertyP. Promiscuity of fibroblast growth factor receptors. Bioessays1996;18:639–646.
51.
Komi-KuramochiAKawanoMOdaY, et al.Expression of fibroblast growth factors and their receptors during full-thickness skin wound healing in young and aged mice. J Endocrinol2005;186:273–289.
52.
CrossMJClaesson-WelshL. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci2001;22:201–207.
53.
WernerSBreedenMHübnerG, et al.Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J Invest Dermatol1994;103:469–473.
54.
TecilazichFDinhTPradhan-NabzdykL, et al.Role of endothelial progenitor cells and inflammatory cytokines in healing of diabetic foot ulcers. PLoS One2013;8:e83314.
55.
BaoPKodraATomic-CanicM, et al.The role of vascular endothelial growth factor in wound healing. J Surg Res2009;153:347–358.
56.
HanninkMDonoghueDJ. Structure and function of platelet-derived growth factor (PDGF) and related proteins. Biochim Biophys Acta Rev Canc1989;989:1–10.
57.
HeldinC-HWestermarkB. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev1999;79:1283–1316.
58.
HosangMRougeMWipfB, et al.Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol1989;140:558–564.
59.
FredrikssonLLiHErikssonU. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev2004;15:197–204.
60.
BarRSBoesMBoothBA, et al.The effects of Platelet-Derived growth factor in cultured microvessel endothelial cells. Endocrinology1989;124:1841–1848.
61.
NicosiaRFNicosiaSVSmithM. Vascular endothelial growth factor, Platelet-Derived growth factor, and Insulin-Like growth factor-1 Promote rat aortic angiogenesis in vitro. Am J Pathol1994;145:1023–1029.
62.
PepperMSFerraraNOrciL, et al.Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun1992;189:824–831.
63.
PierceGFMustoeTAAltrockBW, et al.Role of platelet-derived growth factor in wound healing. J Cell Biochem1991;45:319–326.
64.
Meier BürgisserGEvrovaOCalcagniM, et al.Impact of PDGF‐BB on cellular distribution and extracellular matrix in the healing rabbit achilles tendon three weeks post‐operation. FEBS Open Bio2020;10:327–337.
65.
TravisTEMauskarNAMinoMJ, et al.Commercially available topical platelet-derived growth factor as a novel agent to accelerate burn-related wound healing. J Burn Care Res2014;35:e321–e329.
66.
DoxeyDLNgMCDillRE, et al.Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci1995;57:1111–1123.
67.
BeerH-DLongakerMTWernerS. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol1997;109:132–138.
68.
BallSGBayleyCShuttleworthCA, et al.Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells. Biochem J2010;427:29–40.
69.
BremHTomic-CanicM. Cellular and molecular basis of wound healing in diabetes. J Clin Invest2007;117:1219–1222.
70.
GreenbergJIShieldsDJBarillasSG, et al.A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature2008;456:809–813.
71.
KampferHSchmidtRGeisslingerG, et al.Wound inflammation in diabetic ob/ob mice: Functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 Activity in Diabetes-Impaired wound healing. Diabetes2005;54:1543–1551.
72.
SyedaMMJingXMirzaRH, et al.Prostaglandin transporter modulates wound healing in diabetes by regulating prostaglandin-induced angiogenesis. Am J Pathol2012;181:334–346.
73.
UchibaMOkajimaKOikeY, et al.Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res2004;95:34–41.
74.
JacksonCJXueMThompsonP, et al.Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen2005;13:284–294.
75.
WhitmontKFulcherGReidI, et al.Low circulating protein C levels are associated with lower leg ulcers in patients with diabetes. BioMed Res Int2013;2013:719570.
76.
WhitmontKReidITrittonS, et al.Treatment of chronic leg ulcers with topical activated protein C. Arch Dermatol2008;144:1479–1483.
77.
JacksonCJXueM. Activated protein C-An anticoagulant that does more than stop clots. Int J Biochem Cell Biol2008;40:2692–2697.
78.
TsimermanGRoguinABacharA, et al.Involvement of microparticles in diabetic vascular complications. Thromb Haemostasis2011;106:310–321.
79.
LeroyerASTedguiABoulangerCM. Role of microparticles in atherothrombosis. J Intern Med2008;263:528–537.
80.
GunesAEErenMAKoyuncuI, et al.Investigation of galectin-3 levels in diabetic foot ulcers. J Wound Care2018;27:843–848.
81.
MarkowskaAILiuF-TPanjwaniN. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med2010;207:1981–1993.
82.
DawsonDWVolpertOVGillisP, et al.Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science1999;285:245–248.
83.
Franco-ChuaireMLRamírez-ClavijoSChuaire-NoackL. Pigment epithelium-derived factor: clinical significance in estrogen-dependent tissues and its potential in cancer therapy. Iran J Basic Med Sci2015;18:837–855.
84.
QiWYangCDaiZ, et al.High levels of pigment epithelium-derived factor in diabetes impair wound healing through suppression of wnt signaling. Diabetes2015;64:1407–1419.
85.
CampbellHDFountainSMcLennanIS, et al.Fliih, a Gelsolin-Related cytoskeletal regulator essential for early mammalian embryonic development. Mol Cell Biol2002;22:3518–3526.
86.
RuzehajiNKopeckiZMelvilleE, et al.Attenuation of flightless i improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes. Diabetologia2014;57:402–412.
87.
ThomasHMAhangarPHofmaBR, et al.Attenuation of flightless i increases human pericyte proliferation, migration and angiogenic functions and improves healing in murine diabetic wounds. Int J Mol Sci2020;21:1–15.
88.
ChaiKXMaJXMurraySR, et al.Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem1991;266:16029–16036.
89.
MiaoRQAgataJChaoL, et al.Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood2002;100:3245–3252.
90.
ShenBHagiwaraMYaoY-Y, et al.Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension2008;51:1358–1365.
91.
FengJDongCLongY, et al.Elevated Kallikrein-binding protein in diabetes impairs wound healing through inducing macrophage M1 polarization. Cell Commun Signal2019;17:60.
92.
JagroopIDaskalopoulouSMikhailidisD. Endothelin-1 and human platelets. Curr Vasc Pharmacol2005;3:393–399.
93.
ThorinEClozelM. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol2010;60:1–26.
94.
KalaniM. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag2008;4:1061–1068.
95.
MotawiTKRizkSMIbrahimIA-R, et al.Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy. Cell Biochem Funct2014;32:155–163.
96.
AticRDeveciE. Endothelin 1, NF-κB, and ADAM-15 expression in diabetic foot wounds. Bratislava Med J2019;120:58–64.
97.
VeithAPHendersonKSpencerA, et al.Therapeutic strategies for enhancing angiogenesis in wound healing. Adv Drug Deliv Rev2019;146:97–125.
98.
PapanasNMaltezosE. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging2008;3:233–240.
99.
MohanVK. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diabetes Res Clin Pract2007;78:405–411.
100.
JoonPHHeunDJYunWK. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg2006;56:394–398.
101.
BerlangaJFernándezJILópezE, et al.Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev2013;15:11–15.
102.
Martí-CarvajalAJGluudCNicolaS, et al.Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev2015;28(10):CD008548.
103.
DasSSinghGBakerAB. Overcoming disease-Induced growth factor resistance in therapeutic angiogenesis using recombinant Co-Receptors delivered by a liposomal system. Biomaterials2014;35:196–205.
104.
RobsonMCMustoeTAHuntTK. The future of recombinant growth factors in wound healing. Am J Surg1998;176:80S–82S.
105.
DhallSSilvaJPLiuY, et al.Release of insulin from PLGA-alginate dressing stimulates regenerative healing of burn wounds in rats. Clin Sci2015;129:1115–1129.
106.
GiriSGiriPEbertS, et al.Skin regeneration in deep second-degree scald injuries either by infusion pumping or topical application of recombinant human erythropoietin gel. Drug Des Dev Ther2015;9:2565–2579.
107.
WenC-THeTXingY-Q. Erythropoietin promotes retinal angiogenesis in a mouse model. Mol Med Rep2014;10:2979–2984.
108.
PfalzgraffABrandenburgKWeindlG. Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol2018;9:1–23.
109.
FréchetteJ-PMartineauIGagnonG. Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res2005;84:434–439.
110.
LacciKMDardikA. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med2010;83:1–9.
